Product Information
DOXEPIN 5% CREAM is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $7.1175 per GM under NDC 00093960995. Its NADAC has been published 129 times since Apr 17, 2024.
FDA first approved this application on Feb 17, 2023. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
The High Outlier badge above means this manufacturer's average price in the doxepin hydrochloride market falls above Q3 + 1.5·IQR across all competing manufacturers. We only apply this flag in markets with four or more competitors. Full definition: glossary → outlier.
Strength
50 mg/g
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093960995
Classification
Generic
Dosage Form
CREAM
Route
TOPICAL
Effective Date
9/23/2026
Active Ingredients
DOXEPIN HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA215408FDA Approved
2/17/2023
TE Code
AB
On Market Since
2/17/2023
Pharmacological Classes
Price Statistics
The NADAC for DOXEPIN 5% CREAM has been published 129 times since Apr 17, 2024, and over the history we have for it it has declined 25.6%. The table below summarizes its recorded NADAC range and movement.
| Current price | $7.1175 per GM |
|---|---|
| All-time high | $9.5612 (May 15, 2024) |
| All-time low | $6.1513 (May 20, 2026) |
| 52-week high | $8.3765 |
| 52-week low | $6.1513 |
| Median price | $7.7135 |
| Average price | $7.6708 |
| Largest weekly change | -12.4% (Jun 19, 2024) |
| Weeks tracked | 129 |
| Tracking since | Apr 17, 2024 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the doxepin hydrochloride market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Teva Pharmaceuticals USA Inc. manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
doxepin hydrochloride market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Tricyclic Antidepressant class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of DOXEPIN 5% CREAM?
The current National Average Drug Acquisition Cost (NADAC) for DOXEPIN 5% CREAM, manufactured by Teva Pharmaceuticals USA Inc., is $7.1175 per GM (NDC 00093960995), effective Sep 30, 2026.
How has the price of DOXEPIN 5% CREAM changed over time?
Over the history we have for it, the NADAC for DOXEPIN 5% CREAM has declined 25.6%. It has been tracked across 129 weekly CMS publications since Apr 17, 2024.
What are the highest and lowest recorded NADAC prices for DOXEPIN 5% CREAM?
Since Apr 17, 2024, the NADAC for DOXEPIN 5% CREAM has ranged from a low of $6.1513 (May 20, 2026) to a high of $9.5612 (May 15, 2024), with a median of $7.7135 per GM.
Are there cheaper alternatives to DOXEPIN 5% CREAM?
No other NADAC-published product currently shares the active ingredient and strength of DOXEPIN 5% CREAM in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures DOXEPIN 5% CREAM?
DOXEPIN 5% CREAM (NDC 00093960995) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.